Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment

Mol Biol Rep. 2013 Feb;40(2):1591-7. doi: 10.1007/s11033-012-2207-6. Epub 2012 Oct 18.

Abstract

The aim of this work was to report two cases of hypereosinophilic syndrome (HES). FIP1L1-PDGFRA fusion was assessed with two protocols at RNA level. The fusion transcript was found positive at the RNA level with both PCR methods in two cases. In this study, the efficiency of imatinib treatment and a dramatic response in two HES cases with multisystemic involvement showing the characteristics of a chronic myeloproliferative disease were presented. Both cases showed complete responses confirming that imatinib mesylate treatment could be successful even in patients with advanced HES having myeloproliferative disease.

Publication types

  • Case Reports

MeSH terms

  • Benzamides / therapeutic use*
  • Humans
  • Hypereosinophilic Syndrome / diagnosis*
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / genetics
  • Imatinib Mesylate
  • Male
  • Middle Aged
  • Molecular Diagnostic Techniques
  • Oncogene Proteins, Fusion / genetics
  • Piperazines / therapeutic use*
  • Polymorphism, Restriction Fragment Length
  • Pyrimidines / therapeutic use*
  • Real-Time Polymerase Chain Reaction
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Treatment Outcome
  • mRNA Cleavage and Polyadenylation Factors / genetics

Substances

  • Benzamides
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha